NIH Awards Fletcher R21 Grant to Advance Novel Treatment Strategy for Aggressive Leukemias
Two-year, $427,625 award supports innovative approach designed to overcome treatment resistance in leukemia
By UMSOP Communications and Marketing
November 20, 2026
Steven Fletcher, PhD, professor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has received a two-year, $427,625 R21 grant from the National Cancer Institute of the National Institutes of Health (NIH) to support research aimed at developing a new generation of targeted therapies for aggressive forms of leukemia.
The project focuses on a protein called menin, which plays a critical role in the development of certain acute leukemias, including leukemias involving KMT2A gene rearrangements. These leukemias account for approximately 10 percent of adult acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) cases and an estimated 80 percent of infant leukemia cases. Despite advances in treatment, the overall five-year survival rate for these leukemias remains about 35 percent.
Using structure-based drug design, Fletcher and collaborators will develop molecules designed to eliminate, rather than simply inhibit, the menin protein. Their goal is to address one of the major challenges facing current menin-targeted therapies: the emergence of drug resistance.
“Current small-molecule inhibitors targeting menin have demonstrated promising activity, but resistance can develop,” said Fletcher. “Our approach is different. Rather than inhibiting the protein, we aim to harness the cell’s own protein degradation machinery to completely remove menin. We hope this strategy will overcome resistance mechanisms and provide a more durable therapeutic response.”
The research will employ engineered molecules known as PROTACs, or proteolysis-targeting chimeras, which are designed to direct disease-causing proteins to the cell’s natural disposal system. Fletcher’s team hopes to identify PROTAC molecules capable of degrading menin even in cases where mutations make conventional inhibitors ineffective.
“We are developing targeted drugs against menin, a protein known to drive leukemia development in both adults and children,” Fletcher explained. “Menin promotes cancer growth through interactions with mutant proteins, including KMT2A fusion proteins, which are more common in pediatric leukemias. Because these therapies are designed to target a specific disease mechanism rather than broadly attacking rapidly dividing cells, they have the potential to be safer than conventional chemotherapy, particularly for pediatric patients.”
If successful, the project could lead to a new class of therapies for patients whose cancers develop resistance to existing treatments.
“Instead of just inhibiting menin, which proceeds through occupancy-driven pharmacology, we are proposing to completely degrade the protein by hijacking the cell’s ubiquitin-proteasome protein degradation system with engineered bifunctional molecules called PROTACs,” Fletcher said. “With other targets, PROTACs have overcome mutational resistance through event-driven pharmacology, and we hope to observe the same with menin.”
The project brings together complementary expertise through a multi-principal investigator collaboration between Fletcher and Curt Civin, MD, a pediatric oncologist, leukemia biology expert, and the Philip A. Zaffere Distinguished Professor of Regenerative Medicine at the University of Maryland School of Medicine. The partnership combines Fletcher’s expertise in medicinal chemistry and drug discovery with Civin’s extensive knowledge of leukemia biology and pediatric cancer research.
“This is fundamentally a drug discovery project,” Fletcher said. “The multi-PI structure pairs an expert in drug design and medicinal chemistry with an expert in leukemia biology, allowing us to evaluate these compounds from both chemical and biological perspectives.”
Fletcher’s laboratory focuses on the rational design of novel therapeutics for cancer and inflammatory diseases. His research spans traditional small-molecule drug discovery, which includes harnessing covalent chemistries, as well as emerging approaches that leverage targeted protein degradation and molecular glue technologies to eliminate disease-causing proteins.
The investigators hope to discover PROTAC molecules that can evade resistance mutations in menin and demonstrate a new strategy for treating leukemia. Ultimately, the research could lay the groundwork for targeted therapies that improve outcomes while reducing the toxic side effects often associated with conventional chemotherapy, particularly for children facing aggressive forms of the disease.
Adding to the significance of the award, Fletcher’s proposal received a perfect impact score during NIH peer review, an especially rare achievement indicating the highest possible rating from every reviewer on the study section.


